Bionet (1784) — Capital Reinvestment Ratio
Latest as of December 2025:
1.34x
Bionet (1784) has a Capital Reinvestment Ratio of 1.34x as of December 2025, meaning it reinvests 1% of its operating cash flow (NT$28.46 Million) in capital expenditures (NT$38.02 Million). See cash generation quality of Bionet to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
1.34x
Capex / Operating Cash Flow
Operating Cash Flow
NT$28.46 Million
TWD
Capital Expenditures
NT$38.02 Million
TWD
Data as of
Dec 2025
Most recent filing
Bionet Capital Reinvestment Ratio (2019–2025)
This chart tracks Bionet's Capital Reinvestment Ratio across 7 annual periods.
Annual Capital Reinvestment Ratio for Bionet (2019–2025)
Year-by-year Capital Reinvestment Ratio for Bionet from 2019 to 2025. For live market cap and broader valuation context, see Bionet (1784) market capitalisation.
| Year | Reinvestment Ratio | Operating CF (TWD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.89x | NT$148.04 Million | NT$132.18 Million | ▲ +52.3% |
| 2024 | 0.59x | NT$176.49 Million | NT$103.49 Million | ▲ +241.5% |
| 2023 | 0.17x | NT$153.09 Million | NT$26.28 Million | ▼ -50.6% |
| 2022 | 0.35x | NT$94.65 Million | NT$32.91 Million | ▼ -71.0% |
| 2021 | 1.20x | NT$13.88 Million | NT$16.66 Million | ▲ +132.6% |
| 2020 | 0.52x | NT$73.66 Million | NT$38.03 Million | ▼ -88.1% |
| 2019 | 4.35x | NT$2.67 Million | NT$11.60 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow